BAG3 increases the invasiveness of uterine corpus carcinoma cells by suppressing miR‑29b and enhancing MMP2 expression

Habata,Shutaro; Iwasaki,Masahiro; Sugio,Asuka; Suzuki,Miwa; Tamate,Masato; Satohisa,Seiro; Tanaka,Ryoichi; Saito,Tsuyoshi

doi:10.3892/or.2015.3831

BAG3 increases the invasiveness of uterine corpus carcinoma cells by suppressing miR‑29b and enhancing MMP2 expression

Authors:
- Shutaro Habata
- Masahiro Iwasaki
- Asuka Sugio
- Miwa Suzuki
- Masato Tamate
- Seiro Satohisa
- Ryoichi Tanaka
- Tsuyoshi Saito
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, Japan
Published online on: March 4, 2015 https://doi.org/10.3892/or.2015.3831
Pages: 2613-2621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately 30% of uterine corpus carcinomas are diagnosed at an advanced stage and have a poor prognosis. Our previous study indicated that BCL2-associated athanogene 3 (BAG3) enhances matrix metalloproteinase-2 (MMP2) expression and binds to MMP2 to positively regulate the process of cell invasion in ovarian cancer cells. Recently, altered miRNA expression patterns were observed in several groups of patients with endometrial cancers. One of the altered miRNAs, miR‑29b, reportedly reduces tumor invasiveness by suppressing MMP2 expression. Our aim in the present study was to examine the relationships among BAG3, miR‑29b and MMP2 in endometrioid adenocarcinoma cells. We found that BAG3 suppresses miR‑29b expression and enhances MMP2 expression, which in turn increases cell motility and invasiveness. Moreover, restoration of miR‑29b through BAG3 knockdown reduced MMP2 expression, as well as cell motility and invasiveness. Collectively, our findings indicate that BAG3 enhances MMP2 expression by suppressing miR‑29b, thereby increasing the metastatic potential of endometrioid adenocarcinomas.

View Figures

View References

1	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
2	Barrena Medel NI, Bansal S, Miller DS, Wright JD and Herzog TJ: Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother. 10:1939–1951. 2009. View Article : Google Scholar : PubMed/NCBI
3	Einbond A and Sudol M: Towards prediction of cognate complexes between the WW domain and proline-rich ligands. FEBS Lett. 384:1–8. 1996. View Article : Google Scholar : PubMed/NCBI
4	Sudol M, Chen HI, Bougeret C, Einbond A and Bork P: Characterization of a novel protein-binding module - the WW domain. FEBS Lett. 369:67–71. 1995. View Article : Google Scholar : PubMed/NCBI
5	Doong H, Vrailas A and Kohn EC: What’s in the ‘BAG’? - A functional domain analysis of the BAG-family proteins. Cancer Lett. 188:25–32. 2002. View Article : Google Scholar : PubMed/NCBI
6	Doong H, Price J, Kim YS, Gasbarre C, Probst J, Liotta LA, Blanchette J, Rizzo K and Kohn E: CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70. Oncogene. 19:4385–4395. 2000. View Article : Google Scholar : PubMed/NCBI
7	Iwasaki M, Homma S, Hishiya A, Dolezal SJ, Reed JC and Takayama S: BAG3 regulates motility and adhesion of epithelial cancer cells. Cancer Res. 67:10252–10259. 2007. View Article : Google Scholar : PubMed/NCBI
8	Suzuki M, Iwasaki M, Sugio A, Hishiya A, Tanaka R, Endo T, Takayama S and Saito T: BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Cancer Lett. 303:65–71. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Nelson KM and Weiss GJ: MicroRNAs and cancer: Past, present, and potential future. Mol Cancer Ther. 7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
11	Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N and Aoki D: MicroRNAs in endometrial cancer. Int J Clin Oncol. 18:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
12	Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S and Leslie KK: microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep. 26:995–1002. 2011.PubMed/NCBI
13	Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 101:241–249. 2010. View Article : Google Scholar
14	Garzon R, Heaphy CE, Havelange V, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood. 114:5331–5341. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sugio A, Iwasaki M, Habata S, Mariya T, Suzuki M, Osogami H, Tamate M, Tanaka R and Saito T: BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecol Oncol. 134:615–623. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mott JL, Kobayashi S, Bronk SF and Gores GJ: miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
17	Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology. 54:1729–1740. 2011. View Article : Google Scholar : PubMed/NCBI
18	Homma S, Iwasaki M, Shelton GD, Engvall E, Reed JC and Takayama S: BAG3 deficiency results in fulminant myopathy and early lethality. Am J Pathol. 169:761–773. 2006. View Article : Google Scholar : PubMed/NCBI
19	Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:541–573. 1993. View Article : Google Scholar : PubMed/NCBI
20	Ogasawara S, Yano H, Momosaki S, Nishida N, Takemoto Y, Kojiro S and Kojiro M: Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep. 13:1043–1048. 2005.PubMed/NCBI
21	Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O and Antonaci S: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer. 97:425–431. 2002. View Article : Google Scholar : PubMed/NCBI
22	Negrini M, Ferracin M, Sabbioni S and Croce CM: MicroRNAs in human cancer: From research to therapy. J Cell Sci. 120:1833–1840. 2007. View Article : Google Scholar : PubMed/NCBI
23	Steele R, Mott JL and Ray RB: MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer. 1:381–387. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Zhang X, Li H, Yu J and Ren X: The role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128. 2013. View Article : Google Scholar : PubMed/NCBI
25	Gebeshuber CA, Zatloukal K and Martinez J: miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009. View Article : Google Scholar : PubMed/NCBI
26	Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW and Fernandez-Zapico ME: Transcriptional suppression of miR-29b-1/miR-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem. 110:1155–1164. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Garzon R, Sun H, et al: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 14:369–381. 2008. View Article : Google Scholar : PubMed/NCBI